Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Confavreux, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Confavreux, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 5, 933-934, May 2002
© 2002 Guarantors of Brain

Editorial

Infections and the risk of relapse in multiple sclerosis

Christian Confavreux1

1 Service de Neurologie A and EDMUS Coordinating Centre, Hôpital Neurologique, Lyon, France

Immune dysregulation, likely to be autoimmune and organ-specific in essence, is a landmark in multiple sclerosis. Not surprisingly, physicians have always been concerned with a possible increase in the risk of multiple sclerosis relapse following an infection. Anecdotal reports have given consistency to this concern.

Several epidemiological studies sharing similar features have already addressed this issue. These were observational, prospective studies. Risk periods were defined as encompassing the onset of the clinical infection with the assumption that if a relapse was observed during the risk period, it could be regarded as being associated with the infection. Control periods were made of the non at-risk periods. The rate of relapses during the risk periods was systematically compared with that of control periods. In the pionneer study of Sibley et al. (1985Go), 170 patients with clinically definite multiple sclerosis were assessed at monthly intervals for a mean of 5.2 years . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
C Potagas, C Mitsonis, L Watier, G Dellatolas, A Retziou, P. Mitropoulos, C Sfagos, and D Vassilopoulos
Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study
Multiple Sclerosis, November 1, 2008; 14(9): 1262 - 1268.
[Abstract] [PDF]

Home page
 Am J EpidemiolHome page
A. Alonso, S. S. Jick, H. Jick, and M. A. Hernan
Antibiotic Use and Risk of Multiple Sclerosis
Am. J. Epidemiol., June 1, 2006; 163(11): 997 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R. D Simmons, A.-L. Ponsonby, I. A. van der Mei, and P. Sheridan
What affects your MS? Responses to an anonymous, Internet-based epidemiological survey
Multiple Sclerosis, April 1, 2004; 10(2): 202 - 211.
[Abstract] [PDF]